The world market “had been in tension from before” the war. And therefore “the impact for us pharmaceutical companies was already quite an important reality. The increase in energy costs has heavily impacted on companies and especially on companies that produce low-cost products”.
All this “involves, as we have already ascertained from a survey of companies, the risks of important shortages, which are not so much on the drugs themselves, but we see them above all on the packaging materials, on the storage, on the logistics. concern, which could “in any case” lead to drug shortages “. To explain it is Massimo Scaccabarozzipresident of Farmindustria.
“We cannot retaliate against end consumers or even against States because drug prices are administered, controlled and negotiated – he specifies – So all the part of the increase in costs must be absorbed by companies. But this was already something present independently from the attack “in Ukraine” and from the war “. However, observes Scaccabarozzi, “the war can worsen this situation” which is taking place on a global level. “We have had increases in the order of 150%. The impact” of the boom in energy costs “we were also showing in the past month. All of this has had further increases” in effect.
“And we begin to have problems of deficiencies and slowdowns not so much on the availability of active ingredients, but for example of packaging materials, ferrules, filters. The fear, concludes the number one of the national drug companies association, is that this conflict you accentuate this situation even more “.